Skip to content

Evaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19

Evaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20080901001165N49
Enrollment
80
Registered
2020-04-25
Start date
2020-03-30
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Covid-19

Interventions

Intervention 1: Intervention group: Herbal nasal spray 1 puff every 8 hours, for 7 days (In addition to routine treatment according to the latest national guideline for the treatment of new corona-vir

Sponsors

Andisheh Salamat Sabalan Medicinal Plants Company
Lead Sponsor
Sina Darou Laboratories Company
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age: equal or more than 18 years; The patient have written consciously and freely consent to participate in the study. The patient's clinical symptoms (dry cough, shortness of breath, fever) confirm COVID-19. Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation. Less than 7 days have passed since the onset of symptoms.

Exclusion criteria

Exclusion criteria: History of allergy to this herbal nasal spray ingredients; Hypersensitivity reaction while taking this herbal nasal spray; The patient is in another clinical trial at the same time; The patient needs to receive medical care from the intensive care unit; Patient with uncontrolled hypertension; Hypokalemia (Potassium level<3.5 mmol/l); Pregnancy; Lactation.

Design outcomes

Primary

MeasureTime frame
Clinical symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer.

Secondary

MeasureTime frame
Lab. tests changes. Timepoint: Daily monitoring, but the before the intervention initiation (baseline) and day 7 results will recorded on designed checklist. Method of measurement: Blood sample, laboratory analysis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Biganeh

Bagheiat-allah University of Medical Sciences

biganeh75@gmail.com+98 21 8245 5393

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026